Pharmaceuticals
Europe ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis
This report presents a strategic analysis of the Europe ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Europe ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market, offering unmatched value, accuracy and expert insights.
Buy Now
Europe ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Executive Summary
The European Union's fastest-growing economy in 2021 was Ireland, with the country's GDP growing by 13.5 percent that year. With a GDP of almost 3.3 trillion Euros, Germany is by far Europe's largest economy, followed by the United Kingdom at 2.28 trillion Euros and France at 2.27 trillion Euros.
Despite the fact that unemployment in the EU is currently low, the inflation rate hit a new high of 7.8% in March 2022. Going into 2022, Europe's growth rate is anticipated to be 2.7 percent, with Portugal having the fastest growth rate of 5.8 percent and Estonia having the slowest growth rate of one percent
The pharmaceutical industry covers all aspects of medication research, development, production, and distribution. Pharma revenues worldwide reached $1.42 trillion in 2021 due to the market's rapid growth over the previous two decades. With the introduction of new technology as well as more economical and effective manufacturing techniques, the industry has experienced a significant transition. Additionally, the market growth has been positively driven by rising investment flow in this sector.
ADHD (Attention Deficit Hyperactivity Disorder) can manifest in many different ways and has a wide range of potential causes. It is typically first diagnosed in children. Although those who have ADHD are likely to have a genetic predisposition to the condition, environmental factors can also affect how severe the condition is. Stress and conflict often make it worse.
The name of this illness contains the key characteristics. Daydreaming, difficulty focusing, and being easily distracted are all symptoms of attention issues. The term "hyperactivity" describes pacing or restlessness. A person with the disease could be obnoxious or impulsive, struggle in relationships, or be prone to accidents. While impulsivity and hyperactivity frequently get better as a person gets older, attention issues typically persist into adulthood.
The therapeutic market for attention deficit hyperactivity disorder (ADHD) in the Europe region is expected to be worth USD 3.17 billion in 2022, increasing at a CAGR of 8.10% from 2023 to 2030.
Europe ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Size (In USD Bn) (2021-2030F)
.jpg)
Market Dynamics
Market Growth Drivers Analysis
Due to the lack of a cure for this disorder, the prevalence of ADHD is increasing at a faster rate, which drives the Europe market for therapeutics for the condition. Additionally, the market for ADHD therapeutics is primarily driven by the negative effects of unstable lifestyles and food additives on children, which is increasing the prevalence of ADHD in people between the ages of 4 to 17. Additionally, it is predicted that in the near future, the Europe market for ADHD will experience revenue growth due to rising awareness of the syndrome among doctors and patients as well as opinion-based treatment options caused by the absence of routine diagnostic tests.
Market Restraints
The development of the Europe market for ADHD therapeutics is being constrained by the high cost of ADHD medications, poor reimbursement policies, and side effects associated with ADHD medications (such as insomnia, anorexia, dizziness, headaches, and mood changes). The adverse effects of ADHD medications also have a negative impact on patients' quality of life and restrain the market's revenue growth over the course of the given forecast period. Aside from these issues, medications for attention deficit hyperactivity disorder are linked to medical conditions like kidney disease, coronary artery disease, and seizures.
Competitive Landscape
Key Players
The prominent players operating in this market include Pfizer (US), Eli Lily & Company (US), Johnson & Johnson Services, LLC (US), Lupin (India), Prude Pharma L.P. (US), Shire (US), Mallinckrodt (UK) and NEOS Therapeutics Inc (US)
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation
By Drug Type (Revenue, USD Billion):
- Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
- Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine
By Age Group (Revenue, USD Billion):
- Pediatric And Adolescent
- Adult
By Distribution Channel (Revenue, USD Billion):
- Hospital Pharmacies
- Speciality Clinics
- Retail Pharmacies
- e-Commerce
By Psychotherapy (Revenue, USD Billion):
- Behaviour Therapy
- Cognitive Behavioral Therapy
- Interpersonal Psychotherapy
- Family Therapy
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
- Analyzing historical proprietary data collected from multiple projects.
- Regularly updating our existing data sets with new findings and trends.
- Ensuring data consistency and accuracy through rigorous validation processes.
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
- Searching through academic conferences, published research, citations, and social media platforms
- Collecting and compiling diverse data to build a comprehensive and detailed database
- Continuously updating our database with new information to ensure its relevance and accuracy
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
- Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
- Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
- Continuously refreshing our database to ensure that the information remains current and reliable.
- Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
- Merging historical data from secondary research with real-time data from primary research.
- Conducting thorough data validation and cleansing to remove inconsistencies and errors.
- Organizing data into a structured format that is easily accessible and usable for various applications.
- Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
Related reports (by category)
Related reports (by geography)
Pharmaceuticals
Europe Rheumatology Drugs Market Analysis
Pharmaceuticals
Europe Liver Diseases Therapeutics Market Analysis
Pharmaceuticals
Europe Lung Cancer Therapeutics Market Analysis
Healthcare Services
